Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-20 · accession 0001193125-25-293843 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-24 | 2025-11-20 | LAB | Egholm Michael | Pres, CEO, Dir | F - Tax | $1.28 | -63.5K | 5.62M | -1% | -$81.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-20 | F | D | 63,529 | $1.28 | 5,617,837 | D | — | — | (F1) The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively. |